Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery

Drugs in R and D

Volumn 15, Issue 2, 2015, Pages 187-194

  Omar, Hesham R ^a   Enten, Garrett ^b   Karlnoski, Rachel ^b   Ching, Yiu Hei ^b   Mangar, Devanand ^b,c,d   Camporesi, Enrico M ^b,c,d,e  

^a Mercy Medical Center   (United States)

^b Florida Gulf to Bay Anesthesiology   (United States)

^c TAMPA GENERAL HOSPITAL   (United States)

^d Team Health   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BRACHIOCEPHALIC TRUNK; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; FEMORAL VEIN; HEPATIC ARTERY THROMBOSIS; HUMAN; INCIDENCE; LIVER FAILURE; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; NEUROSURGERY; OBSERVATIONAL STUDY; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PLASMA TRANSFUSION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY VASCULAR DISEASE; RADIAL ARTERY; RETROSPECTIVE STUDY; THORAX SURGERY; THROMBOCYTE TRANSFUSION; THROMBOSIS; VEIN THROMBOSIS; ADVERSE EFFECTS; BLOOD TRANSFUSION; HEART SURGERY; HEMORRHAGE; PROCEDURES;

BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84961197690     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-015-0093-9     Document Type: Article

References (30)

1. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost. 1999;82:531-9.
2. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in US hospitals: analysis of hospital records. Ann Intern Med. 2011;154(8):516-22.
3. Mitra B, Phillips L, Cameron PA, Billah B, Reid C. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care. 2010;38:671-7.
4. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2007;18(2): CD005011.
5. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402-5.
6. Scher C, Narine V, Chien D. Recombinant factor VIIa in trauma patients without coagulation disorders. Anesthesiol Clin. 2010; 28:681-90.
7. Repessé X, Au SM, Bréchot N, Trouillet JL, Leprince P, Chastre J, Combes A, Luyt CE. Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review. Crit Care. 2013;17(2):R55.
8. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154:529-40.
9. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012;3:CD005011.
10. Karkouti K, Arellano R, Aye T, Dupuis JY, Kent B, Lee TW, Lin Y, Ralley F, MacAdams C, Mazer CD, Muirhead B, Rheault MR, Rochon A, Syed S, Waters T, Wong B. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report). Can J Anaesth. 2014;61(8):727-35.
11. Haemostasis Registry Final Report. Ten years of data on the use of recombinant activated factor VII in Australia and New Zealand. Available from: http://www.calembeena.com.au/HR_Final%20Report.pdf. Accessed July 2014.
12. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791-800.
13. Zangrillo A, Mizzi A, Biondi-Zoccai G, Bignami E, Calabrò MG, Pappalardo F, Dedola E, Tritapepe L, Marino G, Landoni G. Recombinant activated factor VII in cardiac surgery: a metaanalysis. J Cardiothorac Vasc Anesth. 2009;23(1):34-40.
14. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293-8.
15. Lin Y, Moltzan CJ, Anderson DR, National Advisory Committee on Blood and Blood Products. The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med. 2012;22:383-94.
16. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-64.
17. Karkouti K, Levy JH. Recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg. 2011;113:711-2.
18. Karkouti K, Beattie WS, Crowther MA, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anesth. 2007;54:573-82.
19. Sorour Y, Van Veen JJ, Makris M. Recombinant factor VIIa for unlicensed indications: a definite no or a cautious maybe in selected patients? Int J Clin Pract. 2010;64:1468-71.
20. Guzzetta NA, Russell IA, Williams GD. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg. 2012;115:364-78.
21. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17:R76.
22. Haemostasis Registry Final Report. Ten years of data on the use of recombinant activated factor VII in Australia and New Zealand. Available from: http://www.calembeena.com.au/HR_Final%20Report.pdf. Accessed July 2014.
23. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120(1):21-7.
24. Abdel-Meguid ME. Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Saudi J Anaesth. 2013;7(3):301-4.
25. Andersen ND, Bhattacharya SD, Williams JB, Fosbol EL, Lockhart EL, Patel MB, Gaca JG, Welsby IJ, Hughes GC. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg. 2012;93(6): 1921-1928 (discussion 1928-1929).
26. Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Eur J Cardiothorac Surg. 2011;40(6):1320-7.
27. Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2011;25(6):987-94.
28. Alfirevic A, Duncan A, You J, Lober C, Soltesz E. Recombinant Factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg. 2014;98(2):618-24.
29. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg. 2011;40(6):1314-8.
30. Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery. Ann Thorac Surg. 2008;85(5):1669-76.